Company / Return on Equity (ROE)
Tango Therapeutics, Inc. Return on Equity (ROE) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-29.3%
FY2025
5-year range
-134.6% / -16.9%
FY2021-FY2025
Trend
+55.1%
vs FY2024
Sector context
#95 of 190
Health Care
What the data says
Tango Therapeutics, Inc. reports negative total equity of -29.3% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-29.3% in FY2025 with a 5-year CAGR of +105.3%.
Improved from -40.2% to -29.3% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -12.5pp
- 5-Year Change
- +105.3pp
- 10-Year Change
- -
Sector benchmark
#95 of 190 in Health CareTop 50% of 190This company -29.3% Sector average -50.3%
▼
+41.7% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 55.1% year-over-year.
- Currently 21.0pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2022.
- Lowest return on equity (roe) in the period was in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -29.3% | +55.1% |
| FY2024 | -65.3% | -62.5% |
| FY2023 | -40.2% | -138.0% |
| FY2022 | -16.9% | +87.5% |
| FY2021 | -134.6% | +0.0% |
| FY2020 | -134.6% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026